肥厚型心肌病患者缺血性卒中:伴或不伴心房颤动
心房颤动独立关联死亡、心血管死亡、缺血性卒中等不良结局。法国HCM评分对缺血性卒中的预测和临床效用优于HCM Risk-CVA与CHA2DS2-VASc评分。
要点
- 肥厚型心肌病患者心房颤动患病率高,缺血性卒中风险显著。
- 心房颤动独立关联死亡、心血管死亡及缺血性卒中等不良结局。
- 法国HCM评分预测缺血性卒中的临床效用优于另两个评分。
核心结论
- 肥厚型心肌病患者心房颤动患病率高且缺血性卒中风险显著,心房颤动独立关联更差结局。
- 简易法国HCM评分对缺血性卒中预测良好、校准良好且具临床效用。
研究设计与样本
- 法国纵向队列研究,基于2010至2019年医院诊疗数据库。
- 构建法国HCM评分,并与HCM Risk-CVA和CHA2DS2-VASc评分比较。
主要发现
- 心房颤动独立关联死亡(HR 1.129,95%CI 1.088-1.172)。
- 心房颤动独立关联心血管死亡(HR 1.254,95%CI 1.177-1.337)。
- 心房颤动独立关联缺血性卒中(HR 1.210,95%CI 1.111-1.317)。
- 缺血性卒中的独立预测因素包括高龄、心力衰竭、心房颤动、既往卒中、吸烟和营养不良(均P<0.05)。
关键数值与推荐
- 法国HCM评分、HCM Risk-CVA评分和CHA2DS2-VASc评分的c-index均在0.65至0.70之间,校准良好。
- 合并心房颤动患者中,CHA2DS2-VASc评分较HCM Risk-CVA评分略有改善,但预测能力低于法国HCM评分(P=0.001)。
- 不合并心房颤动患者中,HCM Risk-CVA评分和法国HCM评分预测均显著优于CHA2DS2-VASc评分(均P<0.0001)。
- 决策曲线分析显示法国HCM评分的临床效用最佳。
临床怎么用
- 对肥厚型心肌病患者应评估心房颤动和缺血性卒中风险。
- 法国HCM评分可用于缺血性卒中风险预测,临床效用优于HCM Risk-CVA和CHA2DS2-VASc评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Patients with hypertrophic cardiomyopathy (HCM) have high risk of ischemic stroke (IS), especially if atrial fibrillation (AF) is present. Improvements in risk stratification are needed to help identify those patients with HCM at higher risk of stroke, whether AF is present or not. METHODS: This French longitudinal cohort study from the database covering hospital care from 2010 to 2019 analyzed adults hospitalized with isolated HCM. A logistic regression model was used to construct a French HCM score, which was compared with the HCM Risk-CVA and CHA2DS2-VASc scores using c-indexes and calibration analysis. RESULTS: In 32 206 patients with isolated HCM, 12 498 (38.8%) had AF, and 2489 (7.7%) sustained an IS during follow-up. AF in patients with HCM was independently associated with a higher risk for death (hazard ratio, 1.129 [95% CI, 1.088-1.172]), cardiovascular death (hazard ratio, 1.254 [95% CI, 1.177-1.337]), IS (hazard ratio, 1.210 [95% CI, 1.111-1.317]), and other major cardiovascular events. Independent predictors of IS in HCM were older age, heart failure, AF, prior IS, smoking and poor nutrition (all P<0.05). For the HCM Risk-CVA score, CHA2DS2-VASc score and a French HCM score, all c-indexes were 0.65 to 0.70, with good calibration. Among patients with AF, the CHA2DS2-VASc score had marginal improvement over the HCM Risk-CVA score but was less predictive compared with the French HCM score (P=0.001). In patients without AF, both HCM Risk-CVA score and the French HCM score had significantly better prediction compared with CHA2DS2-VASc (both P<0.0001). Decision curve analysis demonstrated that the French HCM score had the best clinical usefulness of the 3 tested risk scores. CONCLUSIONS: Patients with HCM have a high prevalence of AF and a significant risk of IS, and the presence of AF in patients with HCM was independently associated with worse outcomes. A simple French HCM score shows good prediction of IS in patients with HCM and clinical usefulness, with good calibration.
引用
- Fauchier L, Bisson A, Bodin A, et al. Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation. Stroke. 2021. PMID: 34601900. doi:10.1161/STROKEAHA.121.034213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。